Marker Therapeutics Inc (MRKR) — Titan Protect Analysis

MRKR

Marker Therapeutics Inc

Healthcare · ·

$1.42

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$24M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-8.49

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-77.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$8.00

+463% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 3 analysts covering this stock

About Marker Therapeutics Inc

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1

https://markertherapeutics.com

Country: United States Employees: 5 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.046

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0281

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.428

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-36.7%

Historical annualised return based on price data

Max Drawdown

-85.7%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.43

Moves slightly more than the broader market

52W High

$4.07

65% below the year high

52W Low

$0.81

75% above the year low

Avg Volume

107,998

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.55

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

-224.4%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-338.5%

Profit from core operations before interest and tax

Free Cash Flow

$-5,248,198

Negative — the business is spending more than it generates

Revenue (TTM)

$4M

Total revenue over the last 12 months

Net Income

$-10,896,714

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$10.00

Target Median

$8.00

Target Low

$5.60

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go